Compounds > ac 7954

Page last updated: 2024-12-11

ac 7954

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-(4-chlorophenyl)-3-(2-(dimethylamino)ethyl)isochroman-1-one: a GPR14/urotensin-II receptor agonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	9797568
CHEMBL ID	192359
CHEBI ID	103978
SCHEMBL ID	4794741
MeSH ID	M0454118

Synonyms (19)

Synonym
BRD-A49544621-003-01-0
gtpl2151
ac 7954
NCGC00165955-01
NCGC00165955-02
3-(4-chlorophenyl)-3-(2-dimethylaminoethyl)isochroman-1-one
L000091
3-(4-chloro-phenyl)-3-(2-dimethylamino-ethyl)-isochroman-1-one
bdbm50164424
3-(4-chlorophenyl)-3-(2-(dimethylamino)ethyl)isochroman-1-one
ac-7954 ,
CHEMBL192359 ,
CHEBI:103978
SCHEMBL4794741
Q27074139
HMS3742C15
3-(4-chlorophenyl)-3-[2-(dimethylamino)ethyl]-4h-isochromen-1-one
734528-95-1
AKOS040747752

Research Excerpts

Dosage Studied

Excerpt	Relevance	Reference
" Group 2 received only paracetamol (PARA) (administered orally at a dosage of 300 mg/kg)."	( The Role of Urotensin Receptors in the Paracetamol-Induced Hepatotoxicity Model in Mice: Ameliorative Potential of Urotensin II Antagonist. Akpinar, E; Bayir, Y; Halici, Z; Karakus, E; Kose, D; Palabiyik, SS; Yayla, M, 2016)	0.43

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
2-benzopyran
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Urotensin-2 receptor	Homo sapiens (human)	EC50 (µMol)	0.7832	0.0030	0.4669	1.1220	AID240088; AID262799; AID437342; AID485971; AID492900
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Process	via Protein(s)	Taxonomy
signal transduction	Urotensin-2 receptor	Homo sapiens (human)
blood circulation	Urotensin-2 receptor	Homo sapiens (human)
regulation of blood pressure	Urotensin-2 receptor	Homo sapiens (human)
blood vessel diameter maintenance	Urotensin-2 receptor	Homo sapiens (human)
neuropeptide signaling pathway	Urotensin-2 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Process	via Protein(s)	Taxonomy
G protein-coupled receptor activity	Urotensin-2 receptor	Homo sapiens (human)
urotensin II receptor activity	Urotensin-2 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Process	via Protein(s)	Taxonomy
plasma membrane	Urotensin-2 receptor	Homo sapiens (human)
membrane	Urotensin-2 receptor	Homo sapiens (human)
plasma membrane	Urotensin-2 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay ID	Title	Year	Journal	Article
AID492900	Agonist activity against human urotensin 2 receptor expressed in human NIH373 cells assessed as beta-galactosidase activity after 5 days by R-SAT assay	2010	Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13	Optimization of isochromanone based urotensin II receptor agonists.
AID485971	Agonist activity at human urotensin 2 expressed in CHO cells by FLIPR	2010	Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7	Urotensin-II receptor modulators as potential drugs.
AID262799	Activity against human urotensin-2 receptor expressed in NIH3T3 cells	2006	Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7	Novel potent and efficacious nonpeptidic urotensin II receptor agonists.
AID437342	Agonist activity against human urotensin 2 receptor expressed in human NIH373 cells assessed as beta-galactosidase activity after 5 days by R-SAT assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Novel and potent small-molecule urotensin II receptor agonists.
AID492901	Agonist activity against human urotensin 2 receptor expressed in human NIH373 cells assessed as beta-galactosidase activity after 5 days by R-SAT assay relative to Urotensin-2	2010	Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13	Optimization of isochromanone based urotensin II receptor agonists.
AID240088	Agonist activity for human Urotensin 2 receptor	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346328	Human UT receptor (Urotensin receptor)	2005	Bioorganic & medicinal chemistry, Apr-15, Volume: 13, Issue:8	Isochromanone-based urotensin-II receptor agonists.
AID1346328	Human UT receptor (Urotensin receptor)	2002	Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23	Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (53.85)	29.6817
2010's	4 (30.77)	24.3611
2020's	2 (15.38)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	23.45 (24.57)
Research Supply Index	2.64 (2.92)
Research Growth Index	4.45 (4.65)
Search Engine Demand Index	23.28 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (23.45)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (15.38%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (84.62%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	2.13	1	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.13	1	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
sodium dodecyl sulfate Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.	2.02	1	0	organic sodium salt	detergent; protein denaturant
sb-710411 SB-710411: is purported to block U-II-induced contractions in rat isolated aorta, little is known about its specific pharmacological properties	3.12	1	0
sb-611812 SB-611812: urotensin-II antagonist	3.15	1	0
sb 657510 SB 657510: a urotensin II antagonist	2.13	1	0
sb-706375 SB-706375: nonpeptidic urotensin-II receptor antagonist; structure in first source	3.15	1	0
bim 23127 BIM 23127: a neuromedin B receptor antagonist	3.12	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.25	1	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Acute Liver Injury, Drug-Induced [description not available]	0	2.13	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	0	2.13	1	0
Innate Inflammatory Response [description not available]	0	2.13	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.13	1	0
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	0	2.93	1	0